Gastric cancer treatments and survival trends in the United States

Kelly A. Stahl, Elizabeth J. Olecki, Matthew E. Dixon, June S. Peng, Madeline B. Torres, Niraj J. Gusani, Chan Shen

Research output: Contribution to journalArticlepeer-review

Abstract

Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.

Original languageEnglish (US)
Pages (from-to)138-151
Number of pages14
JournalCurrent Oncology
Volume28
Issue number1
DOIs
StatePublished - Feb 2021

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Gastric cancer treatments and survival trends in the United States'. Together they form a unique fingerprint.

Cite this